ReviewDrugs2015
Olodaterol: a review of its use in chronic obstructive pulmonary disease.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.British journal of clinical pharmacology · 2017Pooled it
- Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells.Respiratory research · 2021Article
- Tiotropium/Olodaterol: A Review in COPD.Drugs · 2019Review
- Drug Interactions With Oral Inhaled Medications.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2018Review
- What Does the TOVITO Programme Tell Us about How We Can Manage COPD?Turkish thoracic journal · 2018Review
- Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.International journal of chronic obstructive pulmonary disease · 2016Review
- Tiotropium/Olodaterol: A Review in COPD.Drugs · 2016Review
- Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.International journal of chronic obstructive pulmonary disease · 2016Observational
- A review of nebulized drug delivery in COPD.International journal of chronic obstructive pulmonary disease · 2016Review
- Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol.Therapeutics and clinical risk management · 2015Review
- The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olodaterol (Striverdi(®) Respimat(®)) is an inhaled long-acting β2-adrenoceptor agonist (LABA) indicated as a once-daily maintenance bronchodilator therapy in adults with COPD. Several well-designed phase III trials have assessed use of the drug over 6 or 48 weeks in this patient population. In these studies, once-daily olodaterol improved lung function relative to placebo over 48 weeks of treatment, with such improvements being achieved and maintained within the 24-h dosage interval, supporting its once-daily administration. In addition, combined analyses of 48-week trials indicated that olodaterol reduces rescue medication use and may also improve dyspnoea and health-related quality of life, and crossover studies showed improvements in exercise endurance after 6 weeks of treatment with the drug. Pooled analyses of crossover studies assessing 24-h bronchodilation after 6 weeks of therapy indicated that once-daily olodaterol has a 24-h bronchodilatory profile generally similar to that of once-daily tiotropium bromide and twice-daily formoterol. Olodaterol was generally well tolerated and had an acceptable cardiovascular and respiratory adverse event profile. However, further longer-term and active comparator-controlled studies would be beneficial, including trials powered to assess COPD exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.